WallStSmart
COYA

Coya Therapeutics, Inc. Common Stock

NASDAQ: COYA · HEALTHCARE · BIOTECHNOLOGY

$4.18
-9.24% today

Updated 2026-06-05

Market cap
$115.17M
P/E ratio
P/S ratio
14.51x
EPS (TTM)
$-1.15
Dividend yield
52W range
$4 – $8
Volume
0.2M

Coya Therapeutics, Inc. Common Stock (COYA) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item202020212022202320242025
Total assets$8.75M$4.79M$8.40M$41.26M$44.35M$49.95M
Cash & equivalents$8.72M$4.34M$5.93M$32.63M$38.34M$46.82M
Current assets$8.75M$4.58M$7.18M$41.20M$44.31M$49.94M
Total liabilities$447121.00$1.15M$16.79M$5.63M$4.77M$6.92M
Current liabilities$447121.00$1.15M$3.82M$5.05M$3.82M$5.87M
Long-term debt$12.97M
Shareholder equity$8.30M$3.64M$-8.39M$35.64M$39.58M$43.03M
Retained earnings$-731979.00$-5.62M$-17.87M$-25.86M$-40.74M$-61.96M
Accounts receivable$1000.00$7.50M$730581.00
Inventory
Goodwill

Frequently asked questions

What is Coya Therapeutics, Inc. Common Stock's revenue?

Coya Therapeutics, Inc. Common Stock's trailing twelve-month revenue is $7.94M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is COYA?

In its most recent fiscal year, COYA ran a gross margin of 99.66%, an operating margin of -255.05%, and a net margin of -267.14%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does COYA generate?

COYA produced $-10.74M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is COYA's balance sheet healthy?

COYA holds $46.82M in cash and equivalents against — in long-term debt, on $43.03M of shareholder equity. That debt is best read against the cash flow the business throws off each year.